EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 246 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Study Reinforces Treatment Idea for Cancer with Microsatellite Instability October 2, 2020 How our global activity is tackling cancer prevention in low- and... September 12, 2022 EMA Recommends Granting a Marketing Authorisation for Tebentafusp March 31, 2022 ETV6 Protein Could Be an Important Target for Ewing Sarcoma Treatment March 7, 2023 Load more HOT NEWS Grieving for Your Old Life After Cancer Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused...
